MDT-AP-2234
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- os_event
- false
- age_years
- 6.58
- sex
- F
- new_clusters
- C5
- umap1_2d
- 5.402405735
- umap2_2d
- 4.660232184
- umap1_3d
- 2.308533454
- umap2_3d
- -0.242497558
- umap3_3d
- -1.937444126
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.440
- ALLOGRAFT_REJECTION+0.420
- IL6_JAK_STAT3_SIGNALING+0.420
- INFLAMMATORY_RESPONSE+0.390
- INTERFERON_GAMMA_RESPONSE+0.360
- IL2_STAT5_SIGNALING+0.340
- KRAS_SIGNALING_UP+0.340
- COMPLEMENT+0.310
- KRAS_SIGNALING_DN+0.300
- TNFA_SIGNALING_VIA_NFKB+0.290
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.450
- DNA_REPAIR-0.390
- MYC_TARGETS_V1-0.390
- MYC_TARGETS_V2-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.340
- PROTEIN_SECRETION-0.310
- NOTCH_SIGNALING-0.290
- ADIPOGENESIS-0.230
- GLYCOLYSIS-0.220
- MTORC1_SIGNALING-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG728 | — | — | 0.881 |
| 2 | MNG943 | — | — | 0.873 |
| 3 | SRR1369219 | GTEX | — | 0.860 |
| 4 | MDT-AP-3384 | Med | Medulloblastoma | 0.856 |
| 5 | R212 | — | — | 0.853 |
| 6 | SRR608598 | GTEX | — | 0.852 |
| 7 | SRR1474795 | GTEX | — | 0.852 |
| 8 | SRR1382869 | GTEX | — | 0.852 |
| 9 | SRR8943034 | — | — | 0.845 |
| 10 | MNG303 | — | — | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.340 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.120 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |